https://www.hhs.gov/opioids/sites/default/files/2018-12/naloxone-coprescribing-guidance.pdf

Shah et al. Characteristics of Initial Prescription Episodes and Likelihood of Long-Term Opioid Use — United States, 2006–2015. MMWR, March 17, 2017, Vol. 66, No. 10

Jones, J. D., et al. “No Evidence of Compensatory Drug Use Risk Behavior among Heroin Users after Receiving Take-Home Naloxone.” Addictive Behaviors, vol. 71, 2017, pp. 104–106.

Wagner, K. D., et al. “Evaluation of an Overdose Prevention and Response Training Programme for Injection Drug Users in the Skid Row Area of Los Angeles, CA.” International Journal of Drug Policy, vol. 21,no. 3, 2010, pp. 186–193. 

Bazazi, A.R. et al. “Preventing Opiate Overdose Deaths: Examining Objections to Take-Home Naloxone” Journal of Health Care for the Poor and Underserved, vol. 21,no. 4, 2010.

Farkas, Andrew et al. Pulmonary Complications of Opioid Overdose Treated With Naloxone.

Annals of Emergency Medicine, Volume 75, Issue 1, 39 - 48

Rollins MD, Feiner JR, Lee JM, Shah S, Larson M. Pupillary effects of high-dose opioid quantified with infrared pupillometry. Anesthesiology. 2014;121(5):1037‐1044. https://doi.org/10.1097/aln.0000000000000384

Banta-Green CJ, Coffin PO, Schoeppe JA, Merrill JO, Whiteside LK, Ebersol AK. Heroin and pharmaceutical opioid overdose events: Emergency medical response characteristics. Drug Alcohol Depend. 2017;178:1‐6. https://doi.org/10.1016/j.drugalcdep.2017.04.021.

https://www.drugabuse.gov/news-events/nida-notes/2019/07/drug-use-its-consequences-increase-among-middle-aged-older-adults

Raman SR, Bush C, Karmali RN, Greenblatt LH, Roberts AW, Skinner AC. Characteristics of New Opioid Use Among Medicare Beneficiaries: Identifying High-Risk Patterns. J Manag Care Spec Pharm. 2019;25(9):966‐972. https://www.jmcp.org/doi/pdf/10.18553/jmcp.2019.25.9.966

https://www.mdcalc.com/cows-score-opiate-withdrawal

https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-019-4642-8

NM ASSIST tool: https://www.drugabuse.gov/nmassist/

https://www.cdc.gov/drugoverdose/pdf/prescribing/CDC-DUIP-UrineDrugTesting_FactSheet-508.pdf

DAST010: https://med.dartmouth-hitchcock.org/documents/DAST-10-drug-abuse-screening-test.pdf

CRAFFT Questionnaire: http://crafft.org/about-the-crafft/

Webster LR. Risk Factors for Opioid-Use Disorder and Overdose. Anesth Analg. 2017 Nov;125(5):1741-1748.

Cragg, Amber et al. Risk Factors for Misuse of Prescribed Opioids: A Systematic Review and Meta-Analysis. Annals of Emergency Medicine, Volume 74, Issue 5, 634 – 646

Brummett CM, et al. New Persistent Opioid Use After Minor and Major Surgical Procedures in US Adults. JAMA Surg, 2017:21;15

DiClemente, C. C. , & Prochaska, J. O. (1998). Toward a comprehensive, transtheoretical model of change: Stages of change and addictive behaviors. In W. R. Miller & N. Heather (Eds.), Treating addictive behaviors (2nd ed., pp. 3-24). New York: Plenum.

http://adultmeducation.com/FacilitatingBehaviorChange.html

S. E. Wakeman et al., Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. JAMA Netw Open 3, e1920622 (2020). https://doi.org/10.1001/jamanetworkopen.2019.20622

M. A. Schuckit, Treatment of Opioid-Use Disorders. New England Journal of Medicine 375, 357-368 (2016). https://doi.org/10.1056/NEJMra1604339

Wakeman SE, "Using Science to Battle Stigma in Addressing the Opioid Epidemic: Opioid Agonist Therapy Saves Lives," Am J Med 129, no. 5 (May 2016). https://doi.org/10.1016/j.amjmed.2015.12.028

Wakeman SE, "Language and addiction: choosing words wisely," Am J Public Health 103, no. 4 (Apr 2013). https://doi.org/10.2105/AJPH.2012.301191

ASAM Continuum^TM, "What Are the ASAM Levels of Care?", 2015, accessed 5/31/2020, 2020, https://www.asamcontinuum.org/knowledgebase/what-are-the-asam-levels-of-care/.

Centers for Medicare & Medicaid Services (CMS), "Screening, Brief Intervention, and Referral to Treatment (Sbirt) Services." Medical Learning Network, 2020, accessed 5/31/2020, https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/downloads/SBIRT_Factsheet_ICN904084.pdf.

Goel, A., S. Azargive, J. S. Weissman, H. Shanthanna, J. G. Hanlon, B. Samman, M. Dominicis, et al. "Perioperative Pain and Addiction Interdisciplinary Network (Pain) Clinical Practice Advisory for Perioperative Management of Buprenorphine: Results of a Modified Delphi Process." Br J Anaesth 123, no. 2 (Aug 2019): e333-e42. https://doi.org/10.1016/j.bja.2019.03.044

Providers Clinical Support System. SUD 101 Core Curriculum. https://pcssnow.org/education-training/sud-core-curriculum/

Jones JD, Mogali S, Comer SD. Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend. 2012 Sep 1;125(1-2):8-18 https://pubmed.ncbi.nlm.nih.gov/22857878/

Manchikanti L, Kaye AM, Knezevic NN, et al. Responsible, Safe, and Effective Prescription of Opioids for Chronic Non-Cancer Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines. Pain Physician.2017 Feb; 20(2S):S3-S92 https://pubmed.ncbi.nlm.nih.gov/28226332/

TN Chronic Pain Guidelines and the CDC Guidelines. https://www.tn.gov/health/hcf/pain-management-guidelines.html

Serpell MG. Gabapentin in neuropathic pain syndromes: a randomized, double blind, placebo-controlled trial. Pain 2002; 99(3): 557-566. https://pubmed.ncbi.nlm.nih.gov/12406532/

Goodman CW, Brett AS. A clinical overview of off-label use of gabapentinoid drugs. JAMA Intern Med 2019;179(5):695-701.

Onakpoya IJ, Thomas ET, Lee JJ, et al. Benefits and harms of pregabalin in the management of neuropathic pain: A rapid review and meta-analysis of randomized clinical trials. BMJ Open 2019 Jan 21;9(1):e023600. https://pubmed.ncbi.nlm.nih.gov/30670513/

Gomes T, Juurlink DN, Antoniou T, et al. Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study. PLoS Med. 2017;14(10):e1002396. https://pubmed.ncbi.nlm.nih.gov/28972983/

Scholl L, Seth P, et al. Drug and Opioid-Involved Overdose Deaths — United States, 2013–2017. MMWR. 2019;67(5152);1419–1427. https://www.cdc.gov/mmwr/volumes/67/wr/pdfs/mm675152e1-H.pdf

Li Y, Delcher C, Wei YJ, et al. Risk of Opioid Overdose Associated With Concomitant Use of Opioids and Skeletal Muscle Relaxants: A Population-Based Cohort Study [published online ahead of print, 2020 Feb 5]. Clin Pharmacol Ther. 2020;10.1002/cpt.1807. https://pubmed.ncbi.nlm.nih.gov/32022906/

Qaseem A, et al. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017 (https://www-ncbi-nlm-nih-gov.proxy.library.vanderbilt.edu/pubmed/28192789 )

Derry S, et al. Single fixed-dose oral dexketoprofen plus tramadol for acute postoperative pain in adults. Cochrane Database Syst Rev. 2016:CD012232.

(https://www-ncbi-nlm-nih-gov.proxy.library.vanderbilt.edu/pubmed/27654994 )

Beakley BD. Tramadol, Pharmacology, Side Effects, and Serotonin Syndrome: A Review. Pain Physician 2015; 18:395-400 (http://www.painphysicianjournal.com/current/pdf?article=MjM3OA%3D%3D&journal=89 )

EBM Consult: Tramadol and SSRI Interaction.

http://www.ebmconsult.com/articles/tramadol-interaction-ssri-serotonin-syndrome-mechanism

Wan W. The coronavirus pandemic is pushing America into a mental health crisis. https://www.washingtonpost.com/health/2020/05/04/mental-health-coronavirus/ . The Washington Post. Accessed May 31, 2020.

Sullivan MD. Depression Effects on Long-term Prescription Opioid Use, Abuse, and Addiction. Clin J Pain. 2018;34(9):878-884.

https://publications.tnsosfiles.com/pub/execorders/exec-orders-lee14.pdf